Alexander Pearson to Neoplasm Recurrence, Local
This is a "connection" page, showing publications Alexander Pearson has written about Neoplasm Recurrence, Local.
Connection Strength
0.465
-
Capecitabine after Surgical Salvage in Recurrent Squamous Cell Carcinoma of Head and Neck. Otolaryngol Head Neck Surg. 2017 12; 157(6):995-997.
Score: 0.092
-
BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma. Oral Oncol. 2015 Sep; 51(9):839-47.
Score: 0.080
-
Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma. Oral Oncol. 2024 Feb; 149:106688.
Score: 0.036
-
Validation of the RSClin risk calculator in the National Cancer Data Base. Cancer. 2024 Apr 15; 130(8):1210-1220.
Score: 0.036
-
Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform. Breast Cancer Res Treat. 2022 Nov; 196(1):57-66.
Score: 0.033
-
A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer. Nat Commun. 2022 08 17; 13(1):4829.
Score: 0.033
-
Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
Score: 0.033
-
AL101, a gamma-secretase inhibitor, has potent antitumor activity against adenoid cystic carcinoma with activated NOTCH signaling. Cell Death Dis. 2022 08 05; 13(8):678.
Score: 0.033
-
Mucoepidermoid Carcinoma: A Comparison of Histologic Grading Systems and Relationship to MAML2 Rearrangement and Prognosis. Am J Surg Pathol. 2019 07; 43(7):885-897.
Score: 0.026
-
5T4-Targeted Therapy Ablates Cancer Stem Cells and Prevents Recurrence of Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2017 May 15; 23(10):2516-2527.
Score: 0.022
-
Therapeutic Inhibition of the MDM2-p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas. Clin Cancer Res. 2017 Feb 15; 23(4):1036-1048.
Score: 0.022
-
A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer. Invest New Drugs. 2016 08; 34(4):481-9.
Score: 0.021